The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.
An article from
Dive Brief
The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.
Published July 30, 2026
An FDA advisory panel voted in favor of Replimune's "RP1" on July 30, 2026.
Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote - Replimune Group (NASDAQ:REPL)
FDA Staff Unconvinced Drug for Melanoma Shows Benefit
Replimune defends melanoma drug decisions to adcomm, parrying FDA skepticism
FDA staff say Replimune's pivotal melanoma trial failed to prove RP1 works, pushing down stock
FDA expert committee votes in favor of Replimune’s melanoma treatment
Replimune Lead Drug Trial Data Deemed 'Not Interpretable' by FDA Staff - Replimune Group (NASDAQ:REPL)
Twice-Rejected Melanoma Drug Gets Surprise Love From FDA Panel
Pharmalittle: We're reading about a Novo setback, support for Replimune's melanoma drug, and more
Tracking the FDA expert review of Replimune’s melanoma treatment
FDA staff reiterate concerns about Replimune skin cancer treatment
FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decision despite earlier staff criticism.
Replimune's RP1 faces tough test at upcoming FDA advisory panel meeting
Replimune defends its single-arm RP1 melanoma trial data as an FDA advisory panel prepares to vote on whether results are…
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance…
Replimune will resubmit advanced melanoma drug RP1 to the FDA after two rejections, following the ouster of Commissioner Marty…
FDA staff criticized Replimune's RP1 melanoma drug ahead of an advisory meeting, saying its Phase 2 trial failed to prove…
